Raymond Woo-Jun Jang

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

Simple Prognostic Model for Patients With Advanced Cancer Based on Performance Status

Raymond Woo-Jun Jang, Valerie B. Caraiscos, Nadia Swami et al. · Journal of Oncology Practice · 2014 · 265 citations · Full text

Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy

Lachlan McDowell, Kathy Rock, Wei Xu et al. · International Journal of Radiation Oncology*Biology*Physics · 2018 · 175 citations

Adaptive Radiotherapy, Oncology, Nasopharyngeal Carcinoma Treated +7